Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 10, 2008, Pages 3777-3784

  Colao, Annamaria ^a   Galderisi, Maurizio ^a   Di Sarno, Antonella ^a   Pardo, Moira ^a   Gaccione, Maria ^a   D'Andrea, Marianna ^a   Guerra, Ermelinda ^a   Pivonello, Rosario ^a   Lerro, Giuseppe ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; PULMONARY VALVE INSUFFICIENCY; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION;

EID: 53749084356     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1403     Document Type: Article

References (34)

1. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 5:485-534
2. Nutt JG, Wooten GF 2005 Diagnosis and initial management of Parkinson's disease. N Engl J Med 353:1021-1027
3. Earley CJ 2003 Restless legs syndrome. N Engl J Med 348:2103-2109
4. Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G 2007 Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol 156(Suppl 1):S57-S63
5. Flowers CM, Racoosin JA, Lu SI, Beitz JG 2003 The US Food and Drug Administration's registry of patients with pergolide-associated valve heart disease. Mayo Clin Proc 78:730-731
6. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D 2004 Treatment of Parkinson's disease with pergolide and relation to restrictive valve heart disease. Lancet 363:1179-1183
7. Pinero A, Marcos-Alberca P, Fortes J 2005 Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976-1977
8. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P 2002 Fibrotic valve heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334-336
9. Schade R Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
10. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valve heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
11. Botero M, Fuchs R, Paulus DA, Lind DS 2002 Carcinoid heart disease: a case report and literature review. J Clin Anesth 14:57-63
12. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ 1992 Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117:50-52
13. Jahnichen S, Horowski R, Pertz HH 2005 Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225-228
14. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033
15. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G 2007 Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426-433
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee 2003 The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. Hypertension 42:1206-1252
17. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G 1997 Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579
18. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G 2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252
19. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261
20. Galderisi M, Paolisso G, Tagliamonte MR, Alfieri A, Petrocelli A, de Divitiis M, Varricchio M, de Divitiis O 1997 Is insulin action a determinant of left ventricular relaxation in uncomplicated essential hypertension? J Hypertens 15:745-750
21. Sahn DJ, De Maria A, Kisslo J, Weyman A 1978 Recommendations regarding quantitation of M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072-1083
22. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N 1986 Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450-458
23. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology 2006 Recommendations for chamber quantification. Eur J Echocardiogr 7:79-108
24. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography 2002 Recommendations of Doppler echocardiography: a report from the Doppler Quantification Task Force of the nomenclature and Standard Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 15:167-184
25. Pepi M, Tamborini G, Galli C, Barbier P, Doria E, Berti M, Guazzi M, Fiorentini C 1994 A new formula for echo-Doppler estimation of right ventricular systolic pressure. J Am Soc Echocardiogr 7:20-26
26. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ; American Society of Echocardiography 2003 Recommendations for evaluation of the severity of native valve regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777-802
27. Fukuda S, Song J-M, Gillinov M, McCarty PM, Daimon M, Kongsaerepong V, Thomas PM, Shiota T 2005 Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty. Circulation 111:975-979
28. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G 2003 Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325-331
29. Stephens JW, Price DE, Ionescu A 2007 Dopamine agonists and valve heart disease. N Engl J Med 356:16
30. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E 2008 Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract, in press
31. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O 2008 Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary, in press
32. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM 2008 Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after eight years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab, in press
33. Dunn FG, Chandraratna P, de Carvalho JH, Basta LL, Frohlich ED 1977 Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 26:789-795
34. Vasan RS, Larson MG, Levy D 1995 Determinants of echocardiographic aortic root size. The Framingham Heart Study. Circulation 91:734-740